Drug Discovery World

JUNE 19, 2024

New research has uncovered how different people respond to sepsis based on their genetics, which could lead to the development of targeted therapies. The ultimate aim is for patients to receive the most effective treatment for their sepsis more quickly, based on their immune response rather than their symptoms.

Immune Response 163

Immune Response Treatment Regulations Therapies 163

Drug Discovery World

AUGUST 7, 2023

By enhancing the precision of gene delivery to heart muscle cells and evading the immune response, exoAAV technology has the potential to redefine the use of gene therapy in the cardiovascular disease field.

Therapies 130

Therapies Disease Research Immune Response 130

Drug Discovery World

OCTOBER 25, 2023

Gamida Cell has revealed early data in 10 patients with CD20 positive non-Hodgkin lymphoma as part of an ongoing study of natural killer (NK) cell therapy candidate GDA-201. The post Natural killer cell therapy shows powerful anti-tumour activity appeared first on Drug Discovery World (DDW).

Therapies 130

Therapies Immune Response Science Treatment 130

Drug Discovery World

FEBRUARY 19, 2024

C-peptide levels reached normal levels and there was no indication that the allogeneic HIP p-islet graft induced any immune recognition or any type of immune response at any time. The development of cell therapies that replace the loss of insulin-producing cells could one day offer cures for type 1 diabetes.

Therapies 130

Therapies Immune Response Engineering Trials 130

Drug Discovery World

JANUARY 10, 2023

The US Food and Drug Administration (FDA) has granted Breakthrough Therapy designation for VAX-24, Vaxcyte’s 24-valent pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. . The post Breakthrough Therapy designation for pneumococcal disease vaccine appeared first on Drug Discovery World (DDW).

Vaccine 130

Vaccine Therapies Disease Immune Response 130

Drug Discovery World

SEPTEMBER 28, 2023

The company demonstrated that resminostat is well tolerated and can inhibit tumour growth and proliferation, cause tumour regression, and strengthen the body’s immune response to cancer in the RESMAIN study. The post Orphan status granted to lymphoma maintenance therapy appeared first on Drug Discovery World (DDW).

Therapies 130

Therapies Immune Response FDA Treatment 130

Drug Target Review

JUNE 27, 2023

This ebook delves into the intricate world of cancer therapies, immune system breakthroughs, therapeutic genetic engineering, and groundbreaking advancements in gene editing, featuring insightful interviews with renowned experts in the field.

Therapies 105

Therapies Immune Response Engineering Drugs 105

Science Daily: Pharmacology News

OCTOBER 18, 2023

To convert this immunosuppressive environment into one amenable to an immune response, investigators engineered a novel oncolytic virus that can infect cancer cells and stimulate an anti-tumor immune response.

Therapies 77

Therapies Immune Response Research Virus 77

PLOS: DNA Science

OCTOBER 12, 2023

In the final chapter of my 2012 book The Forever Fix: Gene Therapy and the Boy Who Saved It , I predicted that the technology would soon expand well beyond the rare disease world. Gene therapy clearly hasn’t had a major impact on health care, offering extremely expensive treatments for a few individuals with rare diseases.

Therapies 69

Therapies Immune Response DNA Virus 69

The Pharma Data

AUGUST 16, 2021

Better activation of innate and adaptive immune responses was achieved with CV2CoV, resulting in faster response onset, higher titers of antibodies, and stronger memory B and T cell activation as compared to the first-generation candidate, CVnCoV. “In Induction of innate immunity was investigated via specific cytokine markers.

Immune Response 52

Immune Response Vaccine Virus RNA 52

Drug Discovery World

JANUARY 12, 2024

Researchers in the US have discovered that a type of immune cell in the human body known to be important for allergy and other immune responses can also attack cancer. In the future, these cells could be manufactured, preserved by freezing, and then administered to patients.

Research 291

Research Immune Response Virus Therapies 291

Drug Discovery World

FEBRUARY 24, 2023

For this evaluation, participants underwent an analytical treatment interruption (ATI) in their antiretroviral therapy (ART) for up to 24 weeks. The data show that a higher proportion of HTI+VES-treated participants remained off ART for the full 24 weeks.

Immune Response 130

Immune Response Vaccine Trials Clinical Trials 130

Science Daily: Pharmacology News

JULY 12, 2023

Researchers have demonstrated that a transplant surgical procedure (called 'needle trauma') triggers a profound immune response and causes the death of most grafted dopamine neurons. These findings suggest a path for the 'realistic' use of cell therapy to treat neurodegenerative disorders.

Therapies 71

Therapies Immune Response Disease Research 71

Drug Discovery World

AUGUST 7, 2024

With over 1,000 different HBV-targeted antibodies in the mixture, GIGA-2339 is unlike any therapy currently in development. ” Despite currently available therapies and vaccines, HBV affects more than 296 million people worldwide, resulting in more than 800,000 deaths each year.

Drug Trials 148

Drug Trials FDA Trials Immune Response 148

Drug Discovery World

OCTOBER 21, 2022

While advances in treatment over the last few years have resulted in good overall survival rates for patients with non-metastatic disease (90% five-year survival rate in the US 1 ), outcomes are still poor in certain cancers that do not respond to standard therapies. 3D bioprinted breast cancer tumours.

Therapies 130

Therapies Small Molecule Immune Response Engineering 130

Plenge Gen

APRIL 7, 2020

Repurposing of approved therapies is the fastest way to impact patients today, as these medicines have regulatory approval to enable investigator-initiated trials and have a manufacturing process to ensure drug supply. (You can download a pdf copy of the blog here.) appeared first on Plenge Gen @rplenge.

Immune Response 52

Immune Response Disease Clinical Trials Drugs 52

Drug Discovery World

MARCH 19, 2024

AT-108 is a first-in-class, off-the-shelf gene therapy that directly reprogrammes tumour cells into antigen-presenting dendritic cells, ultimately leading to a personalised anti-tumour immune response. We believe this breakthrough strategy will give rise to the next generation of cell therapies.

Immune Response 130

Immune Response Packaging Therapies FDA 130

Drug Discovery World

SEPTEMBER 6, 2022

DDW Editor Reece Armstrong looks at the cell and gene therapy landscape, examining the challenges facing developers and the trends we can expect to see throughout the year. . There’s no doubt that cell and gene therapies present some of the most exciting opportunities for emerging drugs. million price point per dose.

Therapies 130

Therapies Clinical Trials Vaccine Disease 130

Drug Discovery World

JULY 12, 2023

However, drugs that reduce inflammation by suppressing the whole immune response also inhibit the immune cells which promote repair. The University of Edinburgh-led study tested multiple drugs in zebrafish larvae for their ability to prevent excessive inflammation during an immune response.

Immune Response 130

Immune Response Drugs Regulations Treatment 130

Alta Sciences

JUNE 11, 2024

My Attendance at the 2024 Boston Society Cell and Gene Therapy Conference pmjackson Tue, 06/11/2024 - 20:49 , via Wikimedia Commons" data-entity-type="file" data-entity-uuid="c7a7fa8b-b2fe-4d84-a75e-d1ba3a4e2caf" src="[link] width="742" height="249" loading="lazy" /> Ecm85, CC BY-SA 3.0

Therapies 52

Therapies Molecular Biology Immune Response Science 52

Drug Discovery World

APRIL 12, 2024

The top stories: Genetically engineered dendritic cells enhance lung cancer therapy A study by researchers at the UCLA Health Jonsson Comprehensive Cancer Center in the US suggests that injecting engineered dendritic cells directly into cancerous lung tumours can help promote a stronger immune response.

Immune Response 130

Immune Response Engineering Drugs Therapies 130

Drug Target Review

MARCH 1, 2024

How significant are the results in terms of advancing TCR-T cell therapy and AMP immunotherapy for the treatment of solid tumours? We have already applied this approach to several important tumour targets where enhancements in TCR-T therapy may lead to important gains in clinical benefit, including mutated KRAS, NY-ESO, and HPV E7 antigens.

Immune Response 105

Immune Response Vaccine Therapies Small Molecule 105

Chemical Biology and Drug Design

FEBRUARY 2, 2024

Terpenes are compounds that inhibit the growth of Leishmania spp, Schistosoma spp, and Echinococcus spp, cause changes in parasite ultrastructure, inhibit enzyme activity, and modulate the immune response. Their use in combination therapy decreases the concentration of the reference drug used.

Treatment 100

Treatment Disease Immune Response Therapies 100

The Premier Consulting Blog

APRIL 18, 2024

Development of cell and gene therapies is growing rapidly, given the major advances in genomic technologies and increasing scientific understanding of genetic regulation and immunology. This blog will outline three characteristics of a successful nonclinical program to support entry into clinical trials for a cell or gene therapy product.

Therapies 52

Therapies Clinical Trials Small Molecule Immune Response 52

Drug Target Review

FEBRUARY 21, 2024

Stem cell transplants have saved patients’ lives time and time again, which led us to launch our own Stem Cell Transplant and Cellular Therapy Program. Stem cell transplants primarily help the immune response through the “graft-versus-leukaemia effect,” and we have to manage the “graft versus host effect.”

Therapies 64

Therapies Treatment FDA Approval Vaccine 64

Drug Target Review

JANUARY 23, 2024

Cell-based therapies, such as tumour-infiltrating lymphocyte (TIL) therapy, have also drawn significant attention following promising results in a melanoma trial. Such approaches apply artificial intelligence (AI) and machine learning (ML) to predict mutations most likely to be good targets for the immune system.

Treatment 122

Treatment Immune Response Vaccine Therapies 122

Drug Discovery World

DECEMBER 16, 2022

The investment allows the company to focus on discovering and developing novel small molecule therapies targeting RNA modifying enzymes (RMEs) for oncology and other diseases. . STC-15 triggers both direct cytotoxic and immune response-based efficacy mechanisms in solid tumour and leukaemia models.

RNA 130

RNA Immune Response Small Molecule Therapies 130

Drug Discovery World

JANUARY 12, 2024

Perhaps most importantly, a new antibiotic was found that targets a Gram-negative pathogen, mRNA was used as an effective therapy for a rare liver disease, and a common immune cell was found to attack cancer.

Immune Response 130

Immune Response Vaccine RNA Drugs 130

Advarra

JANUARY 11, 2024

The applications of mRNA-based therapies in cancer research represent one of the next groundbreaking steps toward improved cancer treatments. Adoptive T Cell therapies, therapeutic antibodies, and immunomodulatory proteins represent just some of the potentially beneficial treatment strategies for successful mRNA cancer trials.

Vaccine 52

Vaccine Therapies Clinical Trials Small Molecule 52

Drug Discovery World

AUGUST 2, 2022

Secondary endpoints will evaluate treatment efficacy, including progression-free and overall survival as well as any immune response to NeuroNova. . NeuroNova is an allogeneic “off-the-shelf” therapy comprised of an immortalised Neural Stem Cell (NSC) line loaded with an engineered oncolytic adenovirus. Camaisa. .

Trials 130

Trials FDA Immune Response Clinical Trials 130

Alta Sciences

JANUARY 11, 2024

It is estimated that there are over 6,000 monogenic diseases, affecting over 350 million people worldwide; for these diseases, cell and gene therapy may provide hope for a cure. However, there are significant challenges associated with the successful development of these complex, leading-edge therapies. what is the altascientist?

Therapies 52

Therapies Immune Response Virus Disease 52

Drug Discovery World

JULY 25, 2023

These include two antibodies for modulating immune responses in cancer and autoimmunity, which are being advanced through pharmaceutical partnerships with Novartis and GlaxoSmithKline. Looking forward Triebel says that present I-O therapies is just the beginning of the story.

Immune Response 246

Immune Response Therapies Vaccine Production 246

Broad Institute

MARCH 20, 2024

doi: 10.1038/s41590-024-01792-2 (2024) Scientists used a microscope to visualize an immunity hub (yellow and green) in human lung tumor tissue (blue). Networks of cells are critical in mediating immune responses. How do immune cells organize within tumors to effectively eliminate cancer cells? Nature Immunology.

Immune Response 131

Immune Response Hospitals Research Treatment 131

Drug Discovery World

APRIL 26, 2024

In addition to encoding the target antigens, mRNA vaccines also provide adjuvant properties that amplify the immune response. This is a really finely honed tool”. “This is very much an individualised therapy and it’s far cleverer in some senses than a vaccine,” said Shaw. “It

Clinical Trials 130

Clinical Trials Vaccine Trials Immune Response 130

Drug Discovery World

OCTOBER 13, 2023

The scientists say the tool can help inform the development of vaccines and therapies for SARS-CoV-2 and other rapidly mutating viruses. Another important application of EVEscape would be to evaluate vaccines and therapies against current and future viral variants.

Vaccine 265

Vaccine Virus Medical Schools Immune Response 265

Drug Discovery World

JANUARY 18, 2024

Market opportunity estimated at over US$1 billion Largely due to the CRS risk (which can be life threatening), administration of cancer immunotherapies, such as bispecific antibodies, is currently restricted to specialist cancer centres which limits uptake of these therapies. million cases of cancer by 2030 1,2.

Treatment 163

Treatment Clinical Trials Immune Response Therapies 163

Drug Discovery World

APRIL 11, 2024

Together with my colleagues, I am tackling what is one of the most pressing problems in biotech, the discovery of targets to serve as the basis for new therapies for cancer and infectious diseases. By understanding what triggers the adaptive immune response in “elite responders” we have identified new targets and therapeutic antibodies.

Research 148

Research Immune Response Disease Laboratories 148